Category: Markets
Published: 2026-06-22T22:30:00.000Z
A securities fraud class action lawsuit has been filed against ADMA Biologics for allegedly making materially false statements about revenues and internal controls. The lawsuit covers investors who purchased ADMA securities between August 9, 2024 and March 25, 2026. The stock dropped 29.1% after Culper Research published a report alleging channel stuffing and undisclosed related party transactions. The deadline to seek lead plaintiff status is August 10, 2026.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.